Sign Up For FREE
Health After 50 Alerts!

We value your privacy and will never rent your email address

Health After 50

PCA3 and Gene Fusion: Two New Prostate Cancer Biomarkers in Development

Comments (0)

Biomarkers are substances like prostate-specific antigen (PSA) that can be measured in blood, urine or other body fluids and used to detect or monitor a disease. Researchers are investigating a number of potential biomarkers that, in the future, may improve upon the PSA test's ability to detect prostate cancer and identify potentially life-threatening tumors. Two promising biomarkers are PCA3 and gene fusion. 

PCA3. PCA3 is a test that measures a gene that is overexpressed (60 to 100 times greater) in prostate cancer cells versus noncancerous cells. Cells shed by the prostate containing the PCA3 gene are detectable in the urine. Researchers report that the lower the level of PCA3 in the urine, the less likely prostate cancer is present. Because PCA3 is not produced or is produced only minimally by noncancerous cells, the presence of conditions like benign prostatic hyperplasia (BPH) or infection is less likely to produce falsely elevated PCA3 levels. PCA3 testing is most reliable when done in conjunction with a digital rectal exam (DRE). 

Researchers report that when performed after a DRE, the results from PCA3 testing are valid in 98 percent of the cases. If the test is performed without a DRE, validity drops to 80 percent. Researchers believe that rather than replacing PSA screening, the PCA3 test may help identify or rule out cancer in men with elevated PSA levels but no prostate cancer on the initial biopsy. In addition, some evidence suggests that the test may be useful in helping to identify men who are appropriate candidates for active surveillance. Currently, PCA3 testing is available only through clinical trials in the United States. 

Gene fusions. A gene fusion is a hybrid gene formed from two previously separated genes. Scientists have discovered that many prostate cancer patients have gene fusions involving the ERG and TMPRSS2 genes that create a new gene that is thought to promote the development of prostate cancer -- and, possibly, a more aggressive form of the disease. Gene fusions are now being detected in urine and have promise as new biomarkers for prostate cancer. More research is needed, however, before this method of testing moves into the mainstream.


Posted in Prostate Disorders on June 1, 2011

Medical Disclaimer: This information is not intended to substitute for the advice of a physician. Click here for additional information: Health After 50 Disclaimer

Notify Me

Would you like us to inform you when we post new Prostate Disorders Health Alerts?

Post a Comment


Health After 50 Alerts registered users may post comments and share experiences here at their own discretion. We regret that questions on individual health concerns to the editors cannot be answered in this space.

The views expressed here do not constitute medical advice, and do not represent the position of Scientific American Health After 50 or Remedy Health Media, LLC, which has no responsibility for any comments posted on this site.

Post a Comment

Already a subscriber?


Forgot your password?

New to Health After 50?

Register to submit your comments.



Forgot Password?

Health Topic Pages